Skip to main content
. 2021 Dec 14;3(1):100486. doi: 10.1016/j.xcrm.2021.100486

Figure 1.

Figure 1

Anti-SARS-CoV-2 IgG responses

(A) Post-infection serum IgG levels in SARS-CoV-2 S and RBD protein. The posterior median decay slope and its 95% credible interval are plotted as black and gray lines, respectively.

(B) Pre- (week 0 = before first dose, n = 150 participants) and post-vaccination (week 4 = before second dose, n = 101 participants) as well as HCW control (n = 49) distributions of serum IgG levels to SARS-CoV-2 S and RBD proteins.

(C) Pre- (week 0; n = 30 participants) and post-vaccination (week 1, n = 30 participants, and week 8, n = 21 participants) distributions of anti-S IgG levels to WT (Wuhan-Hu-1) and VOC lineages Alpha, Beta, Gamma, and Delta. Each point represents 1 participant colored by COVID-19 severity.

∗: distributions with non-overlapping 95% confidence interval (CI) of group mean effect size estimated using a Bayesian ANOVA model (Table S2). Median with interquartile range is depicted. Areas of binding values below detection limit are shaded in gray.